CEU 20th Anniversary Lectures - Bioethics Lecture Series

Type: 
Lecture
Audience: 
Open to the Public
Building: 
Nador u. 9, Monument Building
Room: 
Auditorium
Friday, September 30, 2011 - 3:00pm
Add to Calendar
Date: 
Friday, September 30, 2011 - 3:00pm to Friday, October 14, 2011 - 6:00pm

20th Anniversary Events

BIOETHICS LECTURE SERIES 1.

Organized by the Center for Ethics and Law in Biomedicine

September 30, 2011  15:00 – 16:30

Venue: CEU Auditorium

Opening words by John Shattuck, Rector and President

Prof. John Harris

What Is Science For? A magical mystery tour

John Harris FMedSci, is Director of The Institute for Science, Ethics and Innovation and of the Wellcome Strategic Programme in The Human Body, its Scope Limits and Future, School of Law, University of Manchester, where is he is Lord Alliance Professor of Bioethics. He was joint Editor-in-Chief of The Journal of Medical Ethics from 2004 until July 2011 and was a member of The United Kingdom Human Genetics Commission from its foundation in 1999 until August 2010. Books Include: Clones Genes and Immortality (Oxford: Oxford University Press, 1998); John Harris, ed. Bioethics (Oxford Readings in Philosophy Series, Oxford University Press, 2001); Justine C. Burley and John Harris, eds. A Companion to Genethics: Philosophy and the Genetic Revolution (Blackwell’s Companions to Philosophy Series, Oxford: Basil Blackwell, 2002); On Cloning (London: Routledge, 2004), Enhancing Evolution (Princeton: Princeton University Press, 2007).

Public Lecture followed by a discussion moderated by Prof. Judit Sándor

 

BIOETHICS LECTURE SERIES 2.

Organized by the Center for Ethics and Law in Biomedicine

October 11, 2011 15:00-16:30  

Venue: CEU Auditorium

Prof. Inez de Beaufort

Will you still love me when I’m 128?

 Suppose it is possible to significantly expand our lifestyle: what are the ethical problems we will face? This question has generated a lot of debate in the past years with fierce proponents and fierce opponents of the extension of life. Different arguments will be discussed on both an individual and a societal level: e.g. justice and fairness – should every one have access to life prolonging treatments, is there a fair minimum of years to live; how would we deal with views on the good life, will we be bored, will we have different personal careers and how will we look, what rejuvenating enhancements of our appearance would we want.  

Prof. Inez de Beaufort is Professor of Health Care Ethics at Erasmus Medical Center Rotterdam the Netherlands. She has published on beauty and ethics, end of life decisions, personal responsibility for health, obesity, and other themes. She is a member of the European Group of Ethics in Science and New Technologies, an honorary member of the Dutch Health Council, a Member of an Euthanasia Review Committee, member of the Advisory Committee on the Health Care Insurance Package and different other advisory boards.

 

 

BIOETHICS LECTURE SERIES 3.

Organized by the Center for Ethics and Law in Biomedicine

October 14 , 2011, 15:00–16:30

Venue: CEU Auditorium

Prof. Donna Dickenson

Exploitation and choice in the global egg trade: emotive terminology or necessary critique?

It is generally thought that informed consent and choice are key terms in the debate about markets in human tissue, while exploitation is an emotive and outdated  term. I want to suggest the reverse: a revised concept of exploitation can provide a more sophisticated analysis than the standard neo-liberal rhetoric of choice. While emphasis on respecting individual choice in liberal and utilitarian thinkers was originally intended to extend rights to oppressed groups, particularly women, and while it was put to use by feminist groups in the ongoing debates over abortion, it is now too laden with vagueness and pro-market rhetoric to provide explanatory or prescriptive guidance on concrete issues like the rights and wrongs of the global trade in human tissue, particularly human eggs. In this talk I will explore contending definitions of exploitation to arrive at a more nuanced concept, which I will present as a necessary critique of tissue markets—unlike the emotive terminology of choice.